77 related articles for article (PubMed ID: 38603701)
1. Reconstruction and Analysis of the Differentially Expressed IncRNA-miRNA-mRNA Network Based on Competitive Endogenous RNA in Hepatocellular Carcinoma.
Cao D; Wang Y; Li D; Wang L
Crit Rev Eukaryot Gene Expr; 2019; 29(6):539-549. PubMed ID: 32422009
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
3. Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells.
Baek M; Kim M; Choi HI; Binas B; Cha J; Jung KH; Choi S; Chai YG
PLoS One; 2024; 19(4):e0301663. PubMed ID: 38603701
[TBL] [Abstract][Full Text] [Related]
4. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
5. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
6. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
7. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
8. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
9. The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma.
Oura K; Morishita A; Hamaya S; Fujita K; Masaki T
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769116
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
11. Analysis of differentially expressed long non-coding RNAs in LPS-induced human HMC3 microglial cells.
Baek M; Chai JC; Choi HI; Yoo E; Binas B; Lee YS; Jung KH; Chai YG
BMC Genomics; 2022 Dec; 23(1):853. PubMed ID: 36575377
[TBL] [Abstract][Full Text] [Related]
12.
Chen Z; Wei Y; Zheng Y; Zhu H; Teng Q; Lin X; Wu F; Zhou F
Cells; 2022 Nov; 11(23):. PubMed ID: 36497110
[TBL] [Abstract][Full Text] [Related]
13. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges.
Paskeh MDA; Ghadyani F; Hashemi M; Abbaspour A; Zabolian A; Javanshir S; Razzazan M; Mirzaei S; Entezari M; Goharrizi MASB; Salimimoghadam S; Aref AR; Kalbasi A; Rajabi R; Rashidi M; Taheriazam A; Sethi G
Pharmacol Res; 2023 Jan; 187():106553. PubMed ID: 36400343
[TBL] [Abstract][Full Text] [Related]
14. Evolving therapeutic landscape of advanced hepatocellular carcinoma.
Yang C; Zhang H; Zhang L; Zhu AX; Bernards R; Qin W; Wang C
Nat Rev Gastroenterol Hepatol; 2023 Apr; 20(4):203-222. PubMed ID: 36369487
[TBL] [Abstract][Full Text] [Related]
15. Role of a lipid metabolism-related lncRNA signature in risk stratification and immune microenvironment for colon cancer.
Lin Y; Xiao Y; Liu S; Hong L; Shao L; Wu J
BMC Med Genomics; 2022 Oct; 15(1):221. PubMed ID: 36280825
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
